Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma

British Journal of Dermatology

Volumn 159, Issue 2, 2008, Pages 387-393

  Campbell, S M ^a   Morton, C A ^b   Alyahya, R ^c   Horton, S ^a   Pye, A ^a   Curnow, A ^a  

^a ROYAL CORNWALL HOSPITAL   (United Kingdom)

^b Stirling Royal Infirmary   (United Kingdom)

^c Ward 17 Falkirk Community Hospital   (United Kingdom)

Author keywords

Basal cell carcinoma; CP94; Hydroxypyridinone; Iron chelator; Photodynamic therapy

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; AMINOLEVULINIC ACID;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; AGED; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; ARTICLE; BASAL CELL CARCINOMA; CLEARANCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EXCISION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIGHT EXPOSURE; LIVER FUNCTION TEST; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PAIN; PAIN ASSESSMENT; PARALLEL DESIGN; PHOTODYNAMIC THERAPY; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; TOPICAL TREATMENT; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CARCINOMA, BASAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; MIDDLE AGED; PAIN; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; PYRIDONES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 47549112090     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08668.x     Document Type: Article

References (26)

1. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992 55 : 145 57.
2. Morton CA, Brown SB, Collins C et al. Guidelines for topical photodynamic therapy. Br J Dermatol 2002 146 : 552 67.
3. Svanberg K, Andersson T, Killander D et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-aminolaevulinic acid sensitization and laser irradiation. Br J Dermatol 1994 130 : 743 51.
4. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B Biol 1990 6 : 143 8.
5. Thissen MR, Schroeter CA, Neumann HA. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 2000 142 : 338 9.
6. Rhodes LE, De Rie M, Enstrom Y et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Arch Dermatol 2004 140 : 17 23.
7. Peng Q, Warloe T, Berg K et al. 5-ALA based photodynamic therapy. Cancer 1997 79 : 2282 308.
8. Cox TC, Bawden MJ, Martin A, May BK. Human erythroid 5-aminolaevulinate synthase: promoter analysis and identification of an iron-responsive element in the mRNA. EMBO J 1991 10 : 1891 902.
9. Harth Y, Hirshowitz B, Kaplan B. Modified topical photodynamic therapy of superficial skin tumours, utilising aminolevulinic acid, penetration enhancers, red light and hyperthermia. Dermatol Surg 1998 24 : 723 6.
10. Peng Q, Warloe T, Moan J et al. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995 62 : 906 13.
11. Malik Z, Kostenich G, Roitman L et al. Topical application of 5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumours of mice. J Photochem Photobiol B Biol 1995 28 : 213 18.
12. Ortel B, Tanew A, Hönigsmann H. Lethal photosensitisation by endogenous porphyrins of PAM cells - modification by desferrioxamine. J Photochem Photobiol B 1993 17 : 273 8.
13. Hoyes KP, Porter JB. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol 1993 85 : 393 400.
14. Hershko C, Link G, Pinson A et al. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture. Blood 1991 77 : 2049 53.
15. Bech O, Phillips D, Moan J, MacRobert AJ. A hydroxypyridinone (CP94) enhances protoporphyrin IX formation in 5-aminolaevulinic acid treated cells. J Photochem Photobiol B Biol 1997 41 : 136 44.
16. Pye A, Curnow A. Direct comparison of delta-aminolevulinic-acid and methyl-aminolevulinate-derived protoporphyrin IX accumulations potentiated by desferrioxamine or the novel hydroxypyridinone iron chelator CP94 in cultured human cells. Photochem Photobiol 2007 83 : 766 73.
17. Curnow A, MacRobert AJ, Bown SG. Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid. Lasers Surg Med 2006 38 : 325 31.
18. Curnow A, McIlroy BW, Postle-Hacon MJ et al. Enhancement of 5-aminolaevulinic acid induced photodynamic therapy using iron chelating agents. Br J Cancer 1998 78 : 1278 82.
19. Brittenham GM. Development of iron-chelating agents for clinical use. Blood 1992 80 : 569 74.
20. Morton CA, Mackie RM, Whitehurst C et al. Photodynamic therapy for basal cell carcinoma: effect of tumour thickness and duration of photosensitiser application on response. Arch Dermatol 1998 134 : 248 9.
21. Choudry K, Brooke RCC, Farrer W, Rhodes LE. The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 2003 149 : 124 30.
22. Wiegell SR, Stender IM, Na R, Wulf HC. Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. Arch Dermatol 2003 139 : 1173 7.
23. Grapengiesser S, Ericson M, Gudmundsson F et al. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002 27 : 493 7.
24. Chang SC, MacRobert AJ, Bown SG et al. The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study. J Photochem Photobiol B 1997 38 : 114 22.
25. Martin A, Tope W, Grevelink J et al. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Arch Dermatol Res 1995 287 : 665 74.
26. Campbell S, Pye A, Horton S et al. A clinical investigation to determine the effect of pressure injection on the penetration of topical methyl aminolevulinate into nodular basal cell carcinoma of the skin. J Environ Pathol Toxicol Oncol 2007 26 : 295 303.